Halozyme Therapeutics (HALO) PT Raised to $58 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Halozyme Therapeutics (HALO) PT Raised to $73 at JMP Securities
November 1, 2024 3:42 AM EDTJMP Securities analyst Jason Butler raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $73.00 (from $72.00) while maintaining a Market Outperform rating.... More
Halozyme Therapeutics (HALO) Tops Q3 EPS by 31c, provides guidance
October 31, 2024 4:03 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $1.27, $0.31 better than the analyst estimate of $0.96. Revenue for the quarter came in at $290 million versus the consensus estimate of $251.06 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $4.00-$4.20, versus the consensus of $3.96.... More
